CyclinD1, a prominent prognostic marker for endometrial diseases

Abstract

PurposeAlteration of CyclinD1 was suggested to relate with development of endometrial carcinogenesis before, however CyclinD1 expression is not well defined in endometrial hyperplasia lesions. We checked the relationship between its expression and clinic-pathological variables of endometrial lesions to explore the possibility for CyclinD1 as a potential diagnostic and prognostic marker.MethodsCyclin D1 immunohistochemical analysis (IHC) was used to evaluate 201 fixed, paraffin-embedded endometrial samples which included simple hyperplasia (n = 27), atypical complex hyperplasia (ACH) (n = 41), endometrioid carcinoma (n = 103), endometrial serous carcinoma (ESC) (n = 21) and clear cell carcinoma (CCC) (n = 9). A breast cancer with known CyclinD1 expression was selected as a positive control in each immunohistochemistry run. We also performed follow-up study to estimate patients’ prognosis.ResultsCyclinD1 was significantly overexpressed in atypical complex hyperplasia (ACH), endometrioid carcinoma and clear cell carcinoma (CCC). The positive signaling of CyclinD1 was showed less than 40% in simple hyperplasia and endometrial serous carcinoma (ESC). The high expression of CyclinD1 was observed in metastasis carcinoma group more significantly than non-metastasis carcinoma group. Kaplan Meier analysis demonstrated that patients with high CyclinD1 expression had an obviously poor prognosis than patients without CyclinD1 staining (p < 0.05). Moreover, according to multivariate Cox regression analysis, CyclinD1 expression, as crucial as metastasis, was a risk marker for overall survival rate.ConclusionCyclinD1 exhibited a promising potential to predict the prognosis of patients with endometrial carcinoma. However, the statistical analysis demonstrated that CyclinD1 exhibited a poor ability to differentiate neoplastic lesions from non-neoplastic lesions; thus, the application of CyclinD1 only is not so credible for differentiation between benign and malignant lesions.Virtual slidesThe virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1871063048950173.

Coexpression of cyclin D1 and alpha-internexin in oligodendroglial tumors

“…In the present study, we demonstrated that the cyclin D1 LI was consistently higher than the Ki-67 LI. Cyclin D1 is associated with oncogenesis of various types of tumors, including mantle cell lymphoma [24], breast cancer [25], esophageal carcinoma [26], endometrioid carcinoma [27], gastric carcinoma [28], bladder cancer [29], and cholesteatoma [30]. In brain tumors, the expression of cyclin D1 has been reported in medulloblastomas [31].…”

Effect of monoacylglycerol lipase on the tumor growth in endometrial cancer

“…Studies in colorectal cancer have confirmed that downregulation of MAGL leads to decreased expression of Cyclin D1 and Bcl‐2, thereby inhibiting the proliferation of colorectal cancer and promoting tumor apoptosis or/and cell cycle arrest . Cyclin D1, the protein encoded by CCND1, plays an important and positive role during the key rate‐limiting point, the G1 → S phase transition, in the cell cycle, and Bcl‐2 is an antagonistic protein in the process of apoptosis or programmed death and is thought to prolong the survival of cells in tumors. In our study, we used the same experimental scheme to confirm whether MAGL inhibition MAGL resulted in a reduction in Cyclin D1 and Bcl‐2 in EC, which would lead to impairment of tumor pathogenicity.…”

PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/β-Catenin Pathway

“…Studies have revealed that cyclin D1 is implicated in the cell cycle progression of various tumors and is associated with the cell proliferative activity and differentiation of OC. Suppression of cyclin D1 is closely correlated with reduced tumorigenicity [16,17]. In this study, we examined the protein expression of c-myc and cyclin D1 by western blot analysis after PRR11 overexpression.…”